- NewsCategory：
- All Company news Industry news
common105One result
-
1017
WindMIL Therapeutics and University of ≤♠÷←California, Irvine Announce Collabo♣&σration to Collect Bone Ma α₩✘rrow from Patients with Gliomas
WindMIL Therapeutics and Universit★☆y of California, Irvine Announce C$σollaboration to Collect Bone Maα♠'∑rrow from Patients with GliomasWEDNESDAYπ☆, OCTOBER 16, 2019WindM÷>₽IL Therapeutics and the University φ≤π₩of California, Irvine (UCI) today announced₩®α that the first patients have been identified ∑βin an investigator-sponso→↑ red study for the collection of bone&☆≠ marrow from patients with gliomas. Tλhe study will evaluate generaλ₹♥ting marrow infiltrating lymphocytes (M≤±→ILs™) for these patients throφ₹ugh WindMIL’s proprietary cellular acti∏'βvation and expansion process. The study isφσ being conducted at UCI.“Patients suffering wi♠☆ th glioblastoma are in great £φ§Ωneed of new, promising treatmen γts that might advance the current st® ∏ andard of care,” said Daniela A. Bota, M∞←D, PhD, director of the UCI Health Comprehen€'≤sive Brain Tumor Program, senior a☆σ>ssociate dean for clinical research, UCI •←School of Medicine and clinical di♥&rector, UCI Sue & Bill₩€¶ Gross Stem Cell Research Center. “The University→ ↓✘ of California, Irvine is excited to play ↓≈φa key role in resear→←✔σch that may lead to a clinicaαφ₽l trial that enlists the immune system in novel$β≤ ways to fight this terri£₽∏ble disease.”Gliomas∞£✔₹ are the most common of the¥α↕ malignant brain tumors. Glioblastoma, theγ≤ most common glioma, has a five₽'-year survival of le$∞♣ss than 5 percent. A☆₹∑φdditional treatment options <are urgently needed for these patients. Adopt &ive immunotherapy is a possible a±₽pproach for gliomas and the use of Ω'♦ MILs, a cell therap₩♣€∞y that is naturally tumor-spec♦₽Ωific, is one such treatment optio∞αn.The bone marrow is a unique niche←≈ in the immune system to which antigen-experie§™♥nced memory T cells φΩtraffic and are then maintained. WindMIL φ♠has developed a proprietary pro×€δαcess to select, activate and expand the'σse memory T cells into Mγ✘β♥ILs. Because memory T cells ¥Ω®in bone marrow occur as a result of ♦$the immune system’s recognition of tumor antigenδ§s, MILs are specifically suited for adop→₩•♣tive cellular immunotφπherapy and are able to directly eradi₹€♦cate or facilitate eradication of each patient’s α≈unique cancer. WindMIL is currently studying "λ♦MILs in multiple myeloma, non-small cell lun© ¥±g cancer and squamous cell carcinoma of t≈☆™he head and neck, and plans to e¥βεxpand into other solid tumors.“WindMIL is lookiσ∞ng forward to working with t•¥he University of California, Irvine on this excit↓ing project and is optimistic that MILs may off↑☆→er the potential to help patients witΩΩδh these hard-to-treat diseases,"™” said Monil Shah, PharmD, MBA, C∑↑hief Development Officer at WindMIL.information&γ☆₹ nbsp;source:pharma focus As€↓δ☆iaThe original link:https://ww÷Ω∏w.pharmafocusasia.com/news/win≤γεdmil-therapeutics-and-universi'±₽÷ty-of-california-irvine-anβ¶αnounce-collaboration-to-collec★t-bone-marrow-from-patients-with-gliomas2019 Asia₹↔-pacific pharma IP Leader Summit: http://en.zen↕®seegroup.com/p/510934/will be held in Beij♦← ing on November 14-↕"15, and will attract more than 500 industry ex→σperts from domestic and foreign pharmaceuticaφε÷♣l companies, biotechnology companies, government ♦$s, associations, law firm←¶™φs, intellectual property agents and other co↔π§mpanies to attend.OfΩ<φficial registration and consultation c↑≠☆hannels:Contact：AnnPhone: 021-65650305E§ mail：Marketing@zenseegroup.comhttp:/×δ≤/en.zenseegroup.com/p/510934/ -
1016
CRISPR Therapeutics and KSQ Ther☆☆apeutics Announce License Agreement "↓to Advance Companies’ Respective Cell Therapy Prα☆ograms in Oncology
CRISPR Therapeutics and KSQ Therapeutics Announ®$™ce License Agreement to Advance Compa₹≥Ωnies’ Respective Cell Therapy Prog∏♠£ rams in OncologyWEDNESDAY, OCTOBER 16, 2019CRIS×←PR Therapeutics, a biopharmaceutical compε☆αany focused on creating transformative gene-bas₽αed medicines for seri€™♦ous diseases, and KS×₹Q Therapeutics, a biote✘₩×chnology company usiα±>ng CRISPR technology to enable the company$↕’s powerful drug discovery engine•← ¶ to achieve higher proσπbabilities of succes×♣¥s in drug development★¥↕, today announced a license agree£÷αment whereby CRISPR Therapeutics will gain acceαφss to KSQ intellectual property (IP) for & editing certain novel gene targe€&φts in its allogeneic oncσ•"←ology cell therapy programs, and≥$¥ KSQ will gain access to CRISPRφ★→ Therapeutics’ IP for editi$α★ng novel gene targets identified by KSQ as part o¶≠f its current and future eTILTM (engineered t♦±&umor infiltrating lyγ₩Ωmphocyte) cell programs. Thε>e financial terms of the agreem£×©≠ent are not being disclosed. →<“We are thrilled to gain acce✔♣×★ss to CRISPR Therapeutics’ foundational IP esta∏σte through this agreement,” said Dav¥£♣®id Meeker, M.D., Chief Executive O♦₽≥↓fficer at KSQ Therapeutics. “Our eTILT™<σ"M programs involve e πσditing gene targets in human TILs that were disco↔Ω×₽vered at KSQ by applying our p↓÷÷roprietary CRISPRomics® approach to immune ce&'§£lls in multiple in vivo models. This agreem ≠ent clears an important path for us to ♥σbe able to bring these programs Ω©through development aγ>£nd commercialization, leveraging CRISPR " Therapeutics’ proprietary ediφ✔ ting technology.”The gen§&e targets within the scope of the license ↑δ∑∏agreement were identified using KSQ’s "¥✘proprietary CRISPRomics® drug discoverβ∑±y engine, which allows genome-scale, in vivo♠↓ validated, unbiased drug discov™γ∏ery. These specific targets we÷¶♠re uncovered in screens to identify gene€♣×tic edits that could enhance¶± the functionality and quality of adoptive ce♠£±ll therapies in oncology.“KSQ h®$δas built an industry-leading p ¥$>latform to screen for novel gene ta♦rgets using its technology,←•♣☆ and has identified a group of targe宧γts that could help unlock the full potential of λσ☆adoptive cell therapy in oncology,” said Sa★ marth Kulkarni, Ph.D., Chieασf Executive Officer "<★at CRISPR Therapeutics. “As a result of this licλ¶ense agreement, CRISPR T&δ₩≤herapeutics will have the opportunity to bri€ →ng these novel targets into our leadin↕∞≠®g allogeneic CAR-T development platform to₹ε&∏ further strengthen our future programs in thi♠±≈s important therapeutic area.”information •✔♠πsource:pharma focus AsiaThe orσ•£λiginal link:https:http☆©' s://www.pharmafocusas≤≥λ ia.com/news/crispr-therapeutics-and-k₩¶₹sq-therapeutics-announc÷'$e-license-agreement-to-advance-com<δ↓panies-respective-cell-tγ↔♠herapy-programs-in-oncology2019♠©≈ Asia-pacific pharma IP Leader Summit: http:✔↑//en.zenseegroup.com/p/510934/ will be held '♦in Beijing on N ×αovember 14-15, and will attract more than 5βλ€×00 industry experts fr∑☆om domestic and foreign pharmaceu✔Ωπ↔tical companies, biotec"✘hnology companies, governme±$®nts, associations, law firms, i÷™ntellectual property agents and other com♣panies to attend.Officia ≈←l registration and consultation channel≠∑♣s:Contact：AnnPhone: 021-6≤ 5650305Email：Marketing@ze₽♥™nseegroup.comhttp://en.zenseegroup.c≥$om/p/510934/ -
1015
Shionogi enters into × $≠a new license agreement and research collaborat€÷→Ωion for the treatment of mycobacσα↑terial diseases with Hsiri T←•herapeutics, Inc.
Shionogi enters into a new license agreementδ<β∞ and research collaboration for the tr★>eatment of mycobacterial diseas£→®es with Hsiri Therapeutics, Inc.MONDAY, OCβ←≈φTOBER 14, 2019Shionogi &®α©∏amp; Co., Ltd. today announced that it has e&£↑✔ntered into a new license δ±agreement with Hsiri Therape£©¶∞utics, Inc. (Head Office: Media, PA, σ© USA; President and CEO: William Clayp₽₹&↕ool, M.D.; hereafter✘↑$↑ "Hsiri") regarding a collaborative research and≠★↔γ development program to discover and deve∏£lop additional novel therapeu♥ ₩tics for non-tuberculous mycobacterial ( ↑✘NTM) diseases and tu σ←berculosis (TB). This new collaboration will incl• £ude technology that complements Shionogi's ea♦™₽$rlier collaboration arrangement with Hsi★δ©ri.The new technology to be licensed from Hsiri ∞φ has a novel mechanism of action$"↓, will be complement→∞≥ary to Shionogi's current research with↕© Hsiri, and is anticipated to be mor ≈≤∏e effective than current therapies for mycoba©♦♠€cterial infections. Shionogi's strength in sma'λ<ll molecule drug discovery and developmentΩ★✔ in the antibacterial area wiλ∑ll support development of Hsiri's iε<¥ nnovative therapeutics in this collabor♣₩βative program. Under∑♣ the terms of this agreeme®$nt, Shionogi will have ≥ε≤exclusive worldwide rights to d® ↑evelop, manufacture, aγ<€nd commercialize the compounds generated from th♥←e collaboration. Hsiri ™will receive an upfront license ≈ fee, potential development milestones, and royalα∞•✘ty payments based on sales from Shionog♥'↑i.It is reported that the number of patients±☆ suffering from NTM diseases has been increasi₽ ng, especially in developed✘£ countries, in recent years. There ★₽is a medical need to develop nov §>el anti-NTM drugs becau♠≥βse of the long duration of treat©¥ment and insufficient treatment outcome of cur¥λrent therapeutics. T✘✘B is one of the three major infectious diseases δ✘in the world, and new cases of TB are estima↔↕ted to be 10.4 million/year. Multidrug-res∑↔"istant TB (MDR-TB) and extensively♦©♦€ drug-resistant TB (XDR-TB) have become a §major public health concern, and novel drugs foσ<r MDR-TB and XDR-TB are anticipated.Shiono®™gi's research and develo•εpment targets infectious disea™¥"se as one of its priority areas, and Shio←λnogi have positioned "protΩ&ecting people from t$☆™✘he threat of infectious diseases" as one oφεf its social mission targets. Through this cooper☆≤ation, Shionogi strives constantly to b₽¶δring forth innovative drugs f→↓Ω♥or the treatment of infectious diseases,★∞ to protect the health σ¶γ§of patients we serve.information ₹₽± source:pharma focus AsiaThe origi↔§ nal link:https:https:htt↔ ps://www.pharmafocusasia.com/ne ∞ws/shionogi-enters-i"×♣nto-a-new-license-agreement-and-σ∑γresearch-collaboration-for-the-treatment-of-m♦•ycobacterial-diseases-with-hsi∑•ri-therapeutics-inc2019 Asia-pacific pharma✔¥® IP Leader Summit: http://en.zenseegroup.com/p/51λ∞' 0934/ will be held in&nb✘∏→γsp;Beijing on November 14-£♣15, and will attract more than 500 industry 'λσexperts from domestic and foreign pharmaceutical ♣Ωcompanies, biotechnology companie ★s, governments, associations, law firms,'γ intellectual property a≤∏♦gents and other companies to attend.Official reg₹×→istration and consultation channels:Contact：An★φnPhone: 021-65650305Email：Marketing$@zenseegroup.comhttp://e←∏ πn.zenseegroup.com/p/510934/ -
1014
Advaxis and UCLA Enter Collaboration fo'±↑r Glioblastoma Immunoth$<erapy Discovery Research
Advaxis and UCLA Enter Collaboration for Gl₹π≤ ioblastoma Immunotherapy Discovery R₽₩esearchFRIDAY, OCTOBER 11, 2019A♦☆♥dvaxis, Inc., a clinical-stage bioteεchnology company focused on the disco€☆±very, development and commercia←∑lization of immunotherapy products, today a ±≤nnounced a research collaboraλ"&tion agreement with the Uni versity of California Los A↔×¥ngeles (UCLA) to conduct preclinical stε< udies evaluating the Compan≤÷₹y’s Lm technology in mou♣✘se tumor models of glioblastoma mul ¶♥tiforme (GBM). Specifically, the c→ε ollaboration with Dr. Vaithi₹ ™ Arumugaswami’s group at UCLA’s Departmαγ ☆ent of Molecular and Medic ♦al Pharmacology will inveλ★stigate anti-tumor immunity and ♣€δanti-tumor responses generated by Lm₩↕ vaccines that express diverse glioblastoma neoan>λ≤βtigens.“We are excited that Dr. Arumugasw™₩π≈ami and his colleagues at UCLA wiβ♣ll investigate the potential&•λ of our Lm technology platfoα¥€€rm in GBM, one of the deadl÷∑iest cancers,” said Andres Gutierrez,<δ≤ Executive Vice President and Chief Medical Of≠÷ficer of Advaxis. “Contrary to₹® other tumor types, GBM has not seen much succe↑∑£ss in targeting by immunotherapeut> ★↕ic agents due to a low tumor mutation burden, × high tumor heterogeneity and prπ↔φesence of the blood brain ₽∑barrier, among other factoσ¶rs. Hence, Dr. Arumugaswami’s charac× ×←terization of the neoantigen land↕↔α♥scape and immune responses to Lm- const™'ructs may lead to the development of n♦"ovel therapies with clinical activity in t₹∞★his elusive cancer.”information source:ph'¥arma focus AsiaThe original γ≈$link:https:https:https://www.phar±γ♦mafocusasia.com/news/advaxis-aσ®↕•nd-ucla-enter-collaboration-for-gliobla≠←≥stoma-immunotherapy-discovery-research2019 As≠§☆✔ia-pacific pharma IP Leader Summit: http://en.∑λ→$zenseegroup.com/p/510934/will be★> held in Beijing on Novembe↑•σ♦r 14-15, and will attract more than 500 industry♠±↕ experts from domestic and fore™εign pharmaceutical companies, biotechγσ✔&nology companies, govern∑≥<ments, associations, law firms, i©≈↕ntellectual property agents an←πd other companies to attend.Official r₽βφ♠egistration and consult≠•ation channels:Contact：AnnPhone: 02±<<1-65650305Email：Marketing@zenseegrou≤>>λp.comhttp://en.zenseegro↑λup.com/p/510934/ -
1011
Viela Bio Enters Strategic Colla€®↑$boration with Mitsubishi€&♥♠ Tanabe Pharma to Develop and Commercialize In<₩<∑ebilizumab for Autoimmune Diseases in Japan and O'♠♦ther Asia Regions
THURSDAY, OCTOBER 10, 2019<÷πViela Bio, Inc. and Mitsubishi Tanabe Pharm≥Ωλa Corporation (“MTPC”) today announced a c₽σ™✘ollaboration focused on the ↕≥development and commercΩ™ialization of inebilizumab – Viela’s hu ∑✔manized anti-CD19 monoclonδ≈✔al antibody – in nine ↕☆Asia regions for neuromyelitis opticα₩a spectrum disorder ∞(NMOSD), as well as other potential fu✔↑λβture indications.“This partne™₩rship adds to our ability™•β to commercialize inebilizumab globally, ↓$♥subject to regulatory approvalγφ ,” commented Bing Yao, Ph.D., ←φα™Viela’s Executive Chairman and Chief Exe®&÷↕cutive Officer. “As a well-δ× established pharmaceutical company in Japa™¥π₹n, Mitsubishi Tanabe has stronγ₹Ω$g product development and &>commercialization capabilities i>α÷n Asia, and we believe, is an id≠≤eal partner for expa<nding inebilizumab’s potential r∞≥each to thousands of ad"βΩ∑ditional patients in need ofφ♥ viable treatments, with NMOSD as an initi≤✘♠×al indication.”Under terms of the colla&αδγboration, Viela will receive a↑φεn up-front licensing fee o♥$f $30 million as well asε© additional payments conting€∑Ωδent on certain development and co×≤↑mmercial milestones, plus payments based, in part σ, on sales revenue. MTPC will b Ωλe responsible for leading devel↓'<opment and commercialization of inebilizuma¶Ωb in Japan, Thailand, South Korea, Indo∞δπnesia, Vietnam, Malaysia, Philippines, € §Singapore, and Taiwan.“Our organization is delig®✘hted to partner with Viela to develop and commeφ↑rcialize their promi←αsing product candidate inebilizumab for autoimm♦αΩune and inflammatory diseases≥',” said Masayuki Mitsuka, MTPC Presidentελ & Representative Director. “Inebilizumab i €s an exciting product candidate that,>£ based on the results ≠∞γfrom the N-MOmentum pi§'votal study, is well-positioned to provide mea♠↔ningful benefit for pat©λ•'ients with NMOSD, and potentially additio&nal diseases, subject to regul&★atory approval. We are excited to work±♣ with Viela to advance inebilizumab Ω≥≈in Japan and other Asia regions,∑• and look forward to a product←₽≈φive partnership between ou≠ λ§r companies.”The U.S. Food and Drug Administratio&↑÷n (FDA) recently accepted for review Viela’s Bioγ¶∏logics License Application (BLA) for inebiliz☆α←umab for the treatment of NMOSD. inform ↔≠ation source:pharma focus AsiaThe¥§↔← original link:https:https://www.pharmafocusaε☆sia.com/news/viela-bio-↑πenters-strategic-collaboration-with-mφ★<≠itsubishi-tanabe-pharma-to-develop-and-commer<ε©♣cialize-inebilizumab-for-autoimmun ₽± e-diseases-in-japan-and-other-asia-r≥'egions2019 Asia-pacific pharm♣✔© a IP Leader Summit: http://en.zenseegroup.com/p/5÷ε10934/will be held i™☆n Beijing on November 14-15, → and will attract more than 500 industry ex∏>β™perts from domestic a£≈nd foreign pharmaceutical companies, biotechno¥≈logy companies, governments, a♠¶₹↔ssociations, law firms, intellectual property€♠£ agents and other companies to attend.O±εfficial registration↕δ and consultation channels:Contact：AnnPho γ>•ne: 021-65650305Email：Marketing@zensee∏ ↔Ωgroup.comhttp://en.zenseegroup.com/p/5&α>10934/
Contact Us
Zensee_Daystar online
© 2011-2016